Prognostic factors and the necessity of chemotherapy for stage II gastric cancer: a model based on multicenter retrospective study

[1]  Fenghua Wang,et al.  The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021 , 2021, Cancer communications.

[2]  Xiaosheng He,et al.  Gastrointestinal cancers in China, the USA, and Europe , 2021, Gastroenterology report.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  Wei Wang,et al.  Impact of examined lymph node count on staging and long-term survival of patients with node-negative stage III gastric cancer: a retrospective study using a Chinese multi-institutional registry with Surveillance, Epidemiology, and End Results (SEER) data validation , 2020, Annals of translational medicine.

[5]  J. Ferlay,et al.  Global burden of oesophageal and gastric cancer by histology and subsite in 2018 , 2020, Gut.

[6]  Wei Wang,et al.  Impact of the number of examined lymph nodes on stage migration in node-negative gastric cancer patients: a Chinese multi-institutional analysis with propensity score matching , 2020, Annals of translational medicine.

[7]  Zhu Minghua,et al.  Impact of Lymph Nodes Examined on Survival in ypN0 Gastric Cancer Patients: a Population-Based Study , 2020, Journal of Gastrointestinal Surgery.

[8]  Japanese Gastric Cancer Association.  Japanese gastric cancer treatment guidelines 2018 (5th edition) , 2020, Gastric Cancer.

[9]  K. Shiu,et al.  Challenges in the treatment of gastric cancer in the older patient. , 2020, Cancer treatment reviews.

[10]  Chang-ming Huang,et al.  Indications for adjuvant chemotherapy in patients with AJCC stage IIa T3N0M0 and T1N2M0 gastric cancer—an east and west multicenter study , 2019, BMC Gastroenterology.

[11]  Lei Tang,et al.  The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer , 2019, Cancer communications.

[12]  Wei Wang,et al.  Validation of clinical significance of examined lymph node count for accurate prognostic evaluation of gastric cancer for the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system , 2018, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[13]  H. Putter,et al.  Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. , 2018, The Lancet. Oncology.

[14]  D. Papamichael,et al.  Management of gastric cancer in older adults. , 2017, Journal of geriatric oncology.

[15]  Y. Doki,et al.  Randomized Controlled Trial of Adjuvant Chemotherapy with Fluoropyrimidines Versus Surgery-alone for Gastric Cancer. , 2017, Anticancer research.

[16]  S. Mocellin.  The Effect of Lymph Node Dissection on the Survival of Patients With Operable Gastric Carcinoma. , 2016, JAMA oncology.

[17]  Soo-Nyung Kim,et al.  Adjuvant Chemotherapy for Advanced Gastric Cancer in Elderly and Non-elderly Patients: Meta-Analysis of Randomized Controlled Trials , 2016, Cancer research and treatment : official journal of Korean Cancer Association.

[18]  Y. Bang,et al.  Is There Any Role of Adjuvant Chemotherapy for T3N0M0 or T1N2M0 Gastric Cancer Patients in Stage II in the 7th TNM but Stage I in the 6th TNM System? , 2016, Annals of Surgical Oncology.

[19]  Yuhong Yuan,et al.  Extent of lymph node dissection for adenocarcinoma of the stomach. , 2015, The Cochrane database of systematic reviews.

[20]  S. Mocellin,et al.  Lymphadenectomy extent and survival of patients with gastric carcinoma: a systematic review and meta-analysis of time-to-event data from randomized trials. , 2015, Cancer treatment reviews.

[21]  P. Kienle,et al.  Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. , 2013, The Cochrane database of systematic reviews.

[22]  Joon-Oh Park,et al.  Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Dazhi Xu,et al.  No Survival Benefit From Postoperative Adjuvant Chemotherapy After D2 Radical Resection for the Patients With Stage II Gastric Cancer , 2011, American journal of clinical oncology.

[24]  P. Schlag,et al.  Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Saif,et al.  Gastric cancer in the elderly: an overview. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[26]  Y. Ohashi,et al.  Randomized controlled trial of adjuvant uracil–tegafur versus surgery alone for serosa‐negative, locally advanced gastric cancer , 2007, The British journal of surgery.

[27]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[28]  Hodgkin Lymphoma.  NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .

[29]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[30]  H. Espejo,et al.  [Gastric cancer]. , 1996, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.